GERD—Barrett—Adenocarcinoma: Do We Have Suitable Prognostic and Predictive Molecular MarkersReportar como inadecuado




GERD—Barrett—Adenocarcinoma: Do We Have Suitable Prognostic and Predictive Molecular Markers - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Gastroenterology Research and PracticeVolume 2013 2013, Article ID 643084, 14 pages

Review Article

Institute of Pathology, Paracelsus Medical University-Salzburger Landeskliniken SALK, Muellner HauptstraBe 48, 5020 Salzburg, Austria

Department of Internal Medicine I, Paracelsus Medical University-Salzburger Landeskliniken SALK, Muellner HauptstraBe 48, 5020 Salzburg, Austria

Received 21 January 2013; Accepted 18 February 2013

Academic Editor: P. Marco Fisichella

Copyright © 2013 Romana Illig et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Due to unfavorable lifestyle habits unhealthy diet and tobacco abuse the incidence of gastroesophageal reflux disease GERD in western countries is increasing. The GERD-Barrett-Adenocarcinoma sequence currently lacks well-defined diagnostic, progressive, predictive, and prognostic biomarkers i providing an appropriate screening method identifying the presence of the disease, ii estimating the risk of evolving cancer, that is, the progression from Barrett’s esophagus BE to esophageal adenocarcinoma EAC, iii predicting the response to therapy, and iv indicating an overall survival—prognosis for EAC patients. Based on histomorphological findings, detailed screening and therapeutic guidelines have been elaborated, although epidemiological studies could not support the postulated increasing progression rates of GERD to BE and EAC. Additionally, proposed predictive and prognostic markers are rather heterogeneous by nature, lack substantial proofs, and currently do not allow stratification of GERD patients for progression, outcome, and therapeutic effectiveness in clinical practice. The aim of this paper is to discuss the current knowledge regarding the GERD-BE-EAC sequence mainly focusing on the disputable and ambiguous status of proposed biomarkers to identify promising and reliable markers in order to provide more detailed insights into pathophysiological mechanisms and thus to improve prognostic and predictive therapeutic approaches.





Autor: Romana Illig, Eckhard Klieser, Tobias Kiesslich, and Daniel Neureiter

Fuente: https://www.hindawi.com/



DESCARGAR PDF




Documentos relacionados